How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world

As underlined in the minireview by Blomstrand et al, given the poor prognosis and the paucity of data on a therapeutic sequence in pancreatic ductal adenocarcinoma (PDAC), additional randomized controlled trials and real-world evidence studies addressing current and novel regimens are needed. The re...

Descripción completa

Detalles Bibliográficos
Autores principales: Pretta, Andrea, Spanu, Dario, Mariani, Stefano, Liscia, Nicole, Ziranu, Pina, Pusceddu, Valeria, Puzzoni, Marco, Massa, Elena, Scartozzi, Mario, Lai, Eleonora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153079/
https://www.ncbi.nlm.nih.gov/pubmed/35662988
http://dx.doi.org/10.5306/wjco.v13.i5.417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153079/
https://www.ncbi.nlm.nih.gov/pubmed/35662988
http://dx.doi.org/10.5306/wjco.v13.i5.417

Ejemplares similares